, a nonintrusive combination with angiotensin II receptor (AT1), is a long-acting, potent angiotensin II receptor (AT1) antagonist that is well controlled throughout the day Blood pressure, more significantly reduced 24h mean systolic blood pressure and 24h mean diastolic blood pressure. Olmesartan Medoxomil is a prodrug that is absorbed orally by the gastrointestinal tract and hydrolyzed to a biologically active product, olmesartan. About olmesartan medoxomil, at least should know the following three points.
First, there is very little interaction between olmesartan
Since olmesartan is not metabolized by the cytochrome P450 enzyme system and does not affect the activity of the P450 enzyme, it usually does not interact with blockers or inducers of the cytochrome P450 enzyme system.
Second, olmesartan can improve sexual function
Hypertension generally requires life-long medication, antihypertensive drugs on the quality of life of patients, especially men's damage to sexual function more and more attention. The current study suggests that diuretics, β-blockers affect male sexual function; ARB can improve sexual function; calcium antagonists generally no significant effect, but some studies have found that it can improve sexual function.
Yuan Bin through clinical research found that: after 24 weeks of treatment, amlodipine had no significant effect on sexual function; Olmesartan Medoxomil erectile function, libido scores were higher than amlodipine group, the difference was statistically significant; olmesartan Estrogen testosterone levels higher than amlodipine group, the difference was statistically significant.
Third, olmesartan can cause severe enteropathy
In July 2013, the U.S. Food and Drug Administration (FDA) approved a change in olmesartan specification stating that olmesartan causes severe enteropathy that may cause stomatitis and diarrhea. Olmesartan is the only angiotensin receptor blocker known to cause this condition.
Olmesartan-related stomatitis diarrhea clinical features: ① gastrointestinal symptoms (chronic diarrhea with weight loss); IgA-anti-tissue transglutaminase antibody negative or anti-endometrial antibody negative; ③ intestinal villous atrophy; ④ exclude other enteropathy (such as celiac disease); â '¢ clinical or histological improvement after the withdrawal of olmesartan.
According to the FDA warning, the use of olmesartan in menarche months, such as severe diarrhea associated with decreased body weight, may be caused by olmesartan severe stomatitis stomatitis, should promptly contact the doctor.